Serum and urine NGAL concentrations were measured in 42 healthy dogs, 11 dogs with chronic kidney disease, 12 dogs with carcinoma, 20 dogs with lymphoma and 15 dogs with lipopolysaccharide-induced endotoxaemia.
In dogs with chronic kidney disease, NGAL was measured 3 and 6 months later.
Compared with healthy controls, dogs with chronic kidney disease (PÄ0·0008), carcinoma (PÄ0·0072) and lymphoma (PÄ0·0008) had elevated serum and urine NGAL and urine NGAL-to-creatinine ratio. Serum and urine NGAL was not significantly different between dogs with chronic kidney disease, carcinoma or lymphoma (Pê0·12).
In dogs with non-progressive chronic kidney disease, NGAL concentrations did not change significantly over the 6-month study period.
NGAL can be elevated by chronic kidney disease and neoplasia, compared with healthy controls. Further research is needed to determine if uNGAL or uNGAL-to-creatinine ratio is more specific than serum levels to detect chronic kidney disease.
Source: Cobrin, A. R., Blois, S. L., Abrams-Ogg, A. C. G., Kruth, S. A., Dewey, C., Holowaychuk, M. K. and Gauthier, V. (2016), Neutrophil gelatinase-associated lipocalin in dogs with chronic kidney disease, carcinoma, lymphoma and endotoxaemia. Journal of Small Animal Practice. doi: 10.1111/jsap.12481
|
